Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 6;3(7):885–898. doi: 10.1038/s43018-022-00391-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 10 — a, Overall survival for the indicated early stage (I, II, III) TCGA ccRCC cohorts based on high proapoptotic NFκB signature (≥median) versus low signature expression. Log-rank test was used to compare the survival between the two groups in each panel. TCGA stage I: Chisq=0.1 on 1 degrees of freedom, p = 0.7; TCGA stage II: Chisq=0.4 on 1 degrees of freedom, p = 0.5; TCGA stage III: Chisq=0.5 on 1 degrees of freedom, p = 0.5. b, NFκB-derived signature analysis of tumors from the CheckMate cohorts of advanced ccRCC examining response (two-sided Wilcoxon rank-sum test) following treatment with PD-1 blockade (left) or mTOR inhibition (right). For PD-1 blockade, CR/PR, n = 39 patients, SD n = 64 patients, PD n = 69 patients. For mTOR inhibition, CR/PR, n = 5 patients, SD n = 67 patients, PD n = 37 patients. Box plot statistical values including whiskers, quartiles, median, max and min values are listed in the Source Data file. c, Overall survival for the mTOR inhibition CheckMate cohort, based on high proapoptotic NFκB signature (≥median) versus low signature expression. Log-rank test was used to compare the survival between the two groups in each panel; Chisq=0.1 on 1 degrees of freedom, p = 0.818.

Source data